Company Profile

Peel Therapeutics Inc
Profile last edited on: 5/19/23      CAGE: 7RFO6      UEI: G1X8J9LJZM78

Business Identifier: Biotech company developing medicines for cancer and inflammatory diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

630 Komas Drive Suite 300
Salt Lake City, UT 84108
   (650) 464-0747
Location: Single
Congr. District: 02
County: Salt Lake

Public Profile

For an extended period after initial founding, PEEL Therapeutics functioned in “stealth mode.” The firm is structured around development of a cancer care platform designed to deliver anti-cancer protein nano-particles -- particles that regulate cellular response to environmental stresses by stimulating transcription of genes involved in cell cycle arrests, cell death and metabolisms, enabling physicians to treat and to cure cancer in humans. The word "Peel" in the firm's name - interestingly speaks to what likely makes the firm of interest. "Peel" is the phonetic spelling of the Hebrew word for elephant - and use of the term serves to reveal a very different and important aspect of the firm's work -- and the fact that it is anchored in study of p53 - a well-known tumor suppressor protein - which the pachyderm has in far greater quality than human along with a mortality rate from cancer that is a small fraction of that found in huma

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Joshua David Schiffman -- Co-Founder and CEO

  Lisa Abegglen -- Project Manager & Scientist

  Patricia Araujo -- Scientist

  Aleah Fox Caulin -- Director of Preclinical Studies

  Trent Fowler -- Director of Operations

  James Levison -- Chief Financial Officer